Cargando…

Development of expression-based biomarkers of Dasatinib response in hematologic malignancies

Detalles Bibliográficos
Autores principales:	Akre, Monica K., Mitra, Amit, Wang, Wen, Myers, Chad L., Van Ness, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802564/ https://www.ncbi.nlm.nih.gov/pubmed/29242603 http://dx.doi.org/10.1038/s41408-017-0013-z

Ejemplares similares

Survival trends in hematological malignancies in the Nordic countries through 50 years
por: Hemminki, Kari, et al.
Publicado: (2022)

Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India
por: Jain, Arihant, et al.
Publicado: (2022)

COVID-19 in Hematologic Malignancies: Big Challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Video-assisted thoracic surgery for ambiguous lung or mediastinal masses in response assessments for hematological malignancies
por: Zheng, Runhui, et al.
Publicado: (2022)

Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review
por: Choi, Jae-Ki, et al.
Publicado: (2018)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro
por: Amrein, Lilian, et al.
Publicado: (2009)

Extracorporeal membrane oxygenation support in patients with hematologic malignancies: to whom and when?
por: Hong, Junshik, et al.
Publicado: (2017)

Characteristics of pathogens detected in adults with hematological malignancies and nosocomial infections in the tropics
por: Dou, Li-Ping, et al.
Publicado: (2020)

Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies
por: Saitta, Claudia, et al.
Publicado: (2022)

Reinfection versus failure of viral clearance in a COVID-19 patient with hematologic malignancy
por: Ibrahim, Moayed, et al.
Publicado: (2021)

High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies()
por: Niu, Alex, et al.
Publicado: (2021)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
por: Tan, Jiaxiong, et al.
Publicado: (2023)

Predictive biomarkers for dasatinib treatment in melanoma
por: Eustace, Alex J., et al.
Publicado: (2014)

Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Multiomics of three hematological malignancies in a patient reveal their origin from clonal hematopoietic stem cells
por: Mayeur, Sylvain, et al.
Publicado: (2023)

NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies
por: Patkar, Nikhil, et al.
Publicado: (2020)

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
por: Marchesi, Francesco, et al.
Publicado: (2023)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib
por: Takekoshi, Daisuke, et al.
Publicado: (2020)

COVID-19 outcomes in patients with hematologic disease
por: Malard, Florent, et al.
Publicado: (2020)

Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma
por: Skoko, Josip, et al.
Publicado: (2018)

BMI1: A Biomarker of Hematologic Malignancies
por: Sahasrabuddhe, Anagh A.
Publicado: (2016)

Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2023)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Response to Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: White, Michael G., et al.
Publicado: (2020)

Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis
por: Raghunandan, Sharmila, et al.
Publicado: (2023)

Prognostic value of serum vascular endothelial growth factor and hematological responses in patients with newly-diagnosed POEMS syndrome
por: Zhao, Hao, et al.
Publicado: (2018)

Reply to Lalonde et al.: Why Would Physiologic Support with Continuous Positive Airway Pressure Not Improve Outcomes in Patients with Atrial Fibrillation with Sleep Apnea?
por: Traaen, Gunn Marit, et al.
Publicado: (2022)

CD markers polymorphisms as prognostic biomarkers in hematological malignancies
por: Shahrabi, Saeid, et al.
Publicado: (2020)

New Clues to Prognostic Biomarkers of Four Hematological Malignancies
por: Salifu, Samson Pandam, et al.
Publicado: (2022)

Does Anemia Cause QT Prolongation in Patients with Hematologic Disorders?
por: Fei, Yu-Dong, et al.
Publicado: (2015)

A Case Report of BCR-ABL-JAK2-Positive Chronic Myeloid Leukemia with Complete Hematological and Major Molecular Response to Dasatinib
por: Ali, Elrazi Awadelkarim Hamid, et al.
Publicado: (2021)

Fine-Mapping of 18q21.1 Locus Identifies Single Nucleotide Polymorphisms Associated with Nonsyndromic Cleft Lip with or without Cleft Palate
por: Mitra, Amit K., et al.
Publicado: (2016)

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014)

LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
por: Kim, Yu Jin, et al.
Publicado: (2016)

Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy: On behalf of CLL commission of Lombardy Hematology Network (REL)
por: Reda, Gianluigi, et al.
Publicado: (2020)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ge5645iuci7ej564dci12tgn2e